Arcus Biosciences, Inc.
RCUS· NYSE
RCUSArcus Biosciences, Inc.
Filed Feb 23, 2022 · 10-K · 54 days after period end · 0000950170-22-001788
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $354.62M | $9.49M | $9.75M | $1.56M |
| Net Income | $279.54M | -$51.85M | -$16.60M | -$12.30M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Feb 23, 2022 · 54 d after period end
